List of Excipients in Branded Drug MIRENA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bayer HealthCare Pharmaceuticals Inc	MIRENA	levonorgestrel	50419-423	BARIUM SULFATE
Bayer HealthCare Pharmaceuticals Inc	MIRENA	levonorgestrel	50419-423	DIMETHICONE

Mirena Excipient Strategy and Commercial Opportunities in Levonorgestrel Intrauterine Systems

Last updated: August 9, 2026

Mirena is a drug-device combination product built around controlled release of 52 mg of levonorgestrel from a silicone reservoir mounted on a polyethylene intrauterine frame. The largest commercial opportunities are not conventional oral-drug excipients. They are in medical-grade silicone systems, membrane engineering, radiopaque polymers, low-extractables materials, insertion-device components, manufacturing controls, and competing intrauterine systems.

Mirena’s core formulation is mature and difficult to displace. A supplier or competitor must match release kinetics, mechanical performance, biocompatibility, sterility, shelf life, insertion reliability, and clinical outcomes. Material substitution alone is unlikely to create a differentiated product unless it improves manufacturing yield, reduces variability, supports a smaller device, lowers cost, or enables a new duration or dose profile.

What excipients and device materials does Mirena use?

Mirena uses a levonorgestrel-silicone drug reservoir rather than a conventional tablet or capsule excipient system.

Component	Function	Commercial relevance
Levonorgestrel	Active pharmaceutical ingredient	Hormonal contraceptive and treatment for heavy menstrual bleeding
Silicone elastomer	Matrix and reservoir material for levonorgestrel	Controls drug diffusion and supports long-term implantation
Silicone membrane	Rate-controlling barrier around the drug reservoir	Critical to release-rate consistency and product duration
Polyethylene	T-shaped intrauterine frame and structural material	Determines flexibility, dimensions, mechanical stability, and insertion behavior
Barium sulfate	Radiopaque additive in the frame	Allows visualization by X-ray or other imaging methods
Polyethylene strings	Retrieval and position-confirmation component	Supports removal and clinical monitoring
Colorant and processing aids	Identification or manufacturing functions	Subject to biocompatibility and extractables controls

The FDA prescribing information identifies Mirena as a levonorgestrel-releasing intrauterine system with a silicone elastomer reservoir and a polyethylene frame containing barium sulfate. The device releases levonorgestrel locally in the uterine cavity over an extended period. The initial release rate is higher and declines over time as the drug reservoir is depleted and diffusion conditions change (U.S. Food and Drug Administration [FDA], 2022).

The relevant regulatory question is whether a material is classified as an inactive ingredient, device constituent, processing aid, color additive, or component of a combination product. For Mirena, the term “excipient” is therefore incomplete. The commercial supply chain is closer to an implantable drug-delivery device than to a conventional pharmaceutical formulation.

How does Mirena’s controlled-release formulation work?

Mirena’s release mechanism depends on diffusion of levonorgestrel through a silicone matrix and rate-controlling membrane. The system is designed to maintain local intrauterine exposure while limiting systemic exposure relative to many oral hormonal products.

The commercial performance of the reservoir depends on:

• Levonorgestrel particle size and distribution
• Drug loading uniformity
• Silicone elastomer composition
• Silicone cross-link density
• Membrane thickness and permeability
• Reservoir geometry
• Cure conditions
• Drug-polymer compatibility
• Sterilization effects
• Storage-related changes in release rate

A supplier that changes silicone grade, silica loading, curing chemistry, or membrane thickness can affect the entire release profile. The change may alter initial burst, total duration, residual drug at removal, or lot-to-lot variability.

For a long-acting intrauterine system, a small deviation in membrane thickness can have a larger commercial effect than a similar deviation in a short-duration dosage form. Process capability, in-line dimensional control, and validated release testing are therefore central parts of the excipient strategy.

Which excipient and material suppliers have the strongest commercial opportunity?

The most attractive opportunities are in specialized, qualified materials rather than commodity excipients.

Medical-grade silicone elastomers

Silicone suppliers can compete through:

• Implantable-grade elastomers
• Consistent low-molecular-weight siloxane profiles
• Controlled silica reinforcement
• Lower extractables and leachables
• Improved cure reproducibility
• Compatibility with levonorgestrel
• Medical-device regulatory documentation
• Stable supply across multiple manufacturing sites

The key value proposition is process control. A cheaper silicone grade has limited value if it increases rejected lots, changes release kinetics, or requires a new clinical and regulatory package.

Silicone membranes and barrier films

Membrane suppliers can target:

• Tighter thickness tolerances
• Better permeability control
• More uniform drug-release rates
• Improved weld or seal performance
• Lower particulate generation
• Higher resistance to sterilization stress
• More efficient roll-to-roll or molded production

Membrane technology is one of the most defensible material opportunities because it directly affects the drug-release profile. A supplier that owns a validated membrane process can become difficult to replace after regulatory approval.

Radiopaque polymers

Barium sulfate-filled polyethylene is a mature technical solution, but suppliers can improve:

• Dispersion uniformity
• Radiopacity at lower filler loading
• Mechanical strength
• Molding consistency
• Surface quality
• Compatibility with sterilization
• Imaging visibility without excessive brittleness

The commercial opportunity is modest for Mirena itself but more significant across the broader intrauterine-device market.

Retrieval strings and identification materials

Retrieval strings are low-cost components with high clinical importance. Opportunities include:

• Improved tensile strength
• Lower fraying
• Better color stability
• Reduced bacterial adhesion
• Consistent knot or attachment performance
• Improved visibility in clinical examination

A string redesign can affect usability and removal performance. It may also trigger new biocompatibility, mechanical, and clinical evaluations.

What formulations are protected by Mirena’s intellectual property?

Mirena’s intellectual-property position historically has included the levonorgestrel reservoir, controlled-release configuration, intrauterine frame, dosage duration, and methods of contraceptive use. The product’s commercial protection has not depended only on the chemical identity of levonorgestrel.

Relevant claim categories include:

1. Drug-polymer reservoir composition.
2. Silicone membrane and diffusion-control structures.
3. Intrauterine frame geometry.
4. Drug loading and release-rate profiles.
5. Insertion and placement systems.
6. Contraceptive and heavy-menstrual-bleeding indications.
7. Manufacturing and assembly methods.

A competitor can avoid a particular formulation claim by changing reservoir architecture, membrane design, drug loading, frame geometry, or manufacturing sequence. That does not eliminate regulatory risk. A materially different device may require new clinical evidence, new stability data, and a separate combination-product strategy.

Mirena is not a biologic, so biosimilar regulation is not relevant. The principal competitive pathways are generic-drug, follow-on combination-product, and independently developed intrauterine-system pathways.

When does Mirena lose exclusivity?

Mirena’s original U.S. approval occurred in 2000. Its initial regulatory exclusivity periods have expired. Commercial entry is now governed mainly by patents, device and combination-product requirements, manufacturing readiness, trademarks, clinical differentiation, and market access.

The product’s approved duration has changed over time. The FDA expanded Mirena’s contraceptive duration to eight years in 2022. The heavy-menstrual-bleeding indication remains limited to five years in the FDA labeling cited here (FDA, 2022).

Milestone	Mirena status
U.S. approval	2000
Initial active ingredient	52 mg levonorgestrel
Current contraceptive duration	Up to 8 years
Heavy menstrual bleeding duration	Up to 5 years
Product category	Drug-device combination product
Biosimilar pathway	Not applicable
Main competitive risks	Follow-on IUS products, generic or abbreviated pathways, device redesigns, lower-cost manufacturing

The eight-year duration creates a commercial advantage for Mirena but also raises the technical threshold for competitors. A rival product must demonstrate stable performance over a long implant period, not merely short-term drug release.

What is the Orange Book status of Mirena?

Mirena is listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, as an approved levonorgestrel intrauterine system. The Orange Book identifies regulatory information relevant to approved drug products, including patent and exclusivity information where applicable (FDA, 2024a).

The Orange Book should not be treated as a complete record of every commercial barrier. For Mirena, the relevant rights may include:

• Listed patents covering the approved drug product
• Device-related patent claims
• Method-of-use claims
• Manufacturing claims
• Trademarks
• Confidential know-how
• Supplier qualification and validation data

An ANDA or similar abbreviated filing can face substantial device-equivalence issues. The applicant must address the active ingredient, delivery system, release profile, dimensions, materials, insertion mechanism, sterility, and clinical performance. A Paragraph IV certification may challenge listed patents, but a successful patent challenge does not automatically establish substitutability or eliminate device-development costs.

Which companies compete with Mirena?

The U.S. hormonal intrauterine-system market includes Bayer’s Mirena, AbbVie’s Liletta through its acquisition of Allergan, and Bayer’s Kyleena and Skyla products. Products differ in levonorgestrel content, approved duration, frame size, insertion system, and approved indications.

Product	Company	Levonorgestrel content	Approved duration or principal positioning
Mirena	Bayer	52 mg	Up to 8 years for contraception; 5 years for heavy menstrual bleeding
Liletta	AbbVie	52 mg	Up to 8 years for contraception; approved for heavy menstrual bleeding
Kyleena	Bayer	19.5 mg	Up to 5 years
Skyla	Bayer	13.5 mg	Up to 3 years

Liletta is the most direct commercial comparator because it uses the same nominal 52 mg levonorgestrel class and competes in long-duration contraception. Kyleena and Skyla target patients and clinicians seeking lower-dose or smaller-system options.

The most defensible differentiation areas are:

• Smaller frame dimensions
• Easier insertion
• Lower insertion force
• Lower expulsion rates
• More predictable bleeding profiles
• Longer duration
• Lower manufacturing cost
• Expanded indications
• Better access through public-health channels

What generic entry risks exist for Mirena?

Mirena faces several forms of entry risk.

Paragraph IV and abbreviated applications

A competitor may challenge listed patents through a Paragraph IV certification. The principal issues would likely involve whether the proposed product infringes listed claims and whether those claims are valid and enforceable.

The litigation value of a Paragraph IV challenge depends on the remaining patent term, claim breadth, regulatory exclusivity, and the cost of proving equivalence for a complex implantable system. An abbreviated route is more difficult than for a conventional levonorgestrel tablet because release behavior is part of the product’s performance.

Follow-on intrauterine systems

A company may develop a product that does not seek direct substitutability with Mirena. It can use different:

• Drug loading
• Reservoir geometry
• Membrane materials
• Frame dimensions
• Insertion mechanism
• Duration
• Indications

This strategy may reduce patent exposure but increase clinical and regulatory costs.

Manufacturing-based entry

A lower-cost supplier can compete without inventing a new formulation if it improves:

• Silicone molding yield
• Reservoir filling
• Membrane assembly
• Automated inspection
• Sterilization throughput
• Packaging
• Device insertion assembly

Manufacturing know-how can be as important as published patent claims. Long-term implants require validated processes that control drug release and maintain sterility through the labeled shelf life.

What FDA regulatory pathway applies to Mirena competitors?

Mirena is regulated as a combination product. The lead center depends on the product’s primary mode of action, with FDA’s Office of Combination Products coordinating jurisdiction where needed. A competitor’s pathway can include:

• An ANDA for a sufficiently comparable drug product
• A 505(b)(2) application for a modified or follow-on product
• A full NDA for a materially different formulation or indication
• A PMA or device-focused submission for a product whose primary mode of action is device-based
• A combination of drug and device submissions

The pathway depends on formulation, release mechanism, device design, intended use, and the degree of reliance on Mirena’s safety and efficacy data. FDA guidance on combination products and abbreviated applications is central to determining the scope of comparative testing (FDA, 2024b).

A commercial program should assume that the following evidence may be required:

• In vitro release testing
• Mechanical and dimensional testing
• Sterility and package-integrity testing
• Extractables and leachables assessment
• Biocompatibility
• Accelerated and real-time stability
• Insertion and removal performance
• Human factors evaluation
• Clinical or comparative pharmacokinetic evidence
• Post-approval manufacturing controls

How strong is Mirena’s patent estate?

Mirena’s patent estate is strongest where formulation, device structure, and use claims overlap. Its practical protection also comes from the complexity of reproducing an eight-year implantable release profile and securing a reliable supply chain.

The estate is weaker against:

• Expired core patents
• Products with different frame designs
• Lower-dose or shorter-duration systems
• Independent clinical development
• Material substitutions that preserve performance
• Manufacturing changes that avoid process claims

Patent strength should be assessed claim by claim, not by counting patent families. Relevant diligence should include the current FDA Orange Book, U.S. Patent and Trademark Office records, district-court dockets, Patent Trial and Appeal Board proceedings, international filings, and settlement agreements.

What licensing deals and commercial partnerships matter?

Bayer developed and markets Mirena. The product’s commercial opportunity is most likely to arise through licensing or supply agreements involving:

• Silicone elastomers
• Drug-release membranes
• Polyethylene molding compounds
• Radiopaque additives
• Insertion devices
• Sterilization
• Contract manufacturing
• Regional distribution
• Public-health procurement

A supplier agreement can create long-term value if the material becomes part of the validated commercial process. The switching cost then includes comparability work, process revalidation, stability studies, regulatory supplements, and supply-risk review.

However, a supplier should not assume that qualification creates broad exclusivity. The customer may dual-source critical materials, retain rights to substitute equivalent grades, or own process patents and tooling.

How large is Mirena’s revenue exposure?

Bayer does not generally disclose Mirena revenue as a standalone line item in its public financial reporting. Mirena is reported within Bayer’s Pharmaceuticals business and women’s health portfolio. Product-level exposure must therefore be estimated from broader segment data, prescription volumes, procedure volumes, pricing, geographic mix, and replacement intervals (Bayer AG, 2024).

The commercial model differs from oral contraceptives:

• Revenue is recognized at product placement rather than through daily dispensing.
• Duration reduces annual replacement frequency.
• Clinician insertion and reimbursement influence demand.
• Upfront device cost is higher than a monthly oral product.
• Public-sector tenders can compress price.
• Competitor entry can affect procurement before it affects retail share.

For excipient and component suppliers, the addressable market is smaller than the branded drug revenue pool. Its value is concentrated in recurring material demand, qualification durability, and the possibility of supplying multiple IUS products.

What commercial opportunities are most attractive?

The strongest opportunities are:

1. Implantable-grade silicone platforms that support reproducible drug diffusion.
2. Membrane technologies with narrow permeability and thickness specifications.
3. Automated reservoir assembly and inspection.
4. Low-extractables materials with global regulatory packages.
5. Smaller intrauterine frames that improve insertion and patient acceptance.
6. Radiopaque polymer systems with improved toughness.
7. Long-duration release platforms for other hormones or noncontraceptive drugs.
8. Contract manufacturing for regional or public-health markets.
9. Digital quality systems that document component genealogy and process capability.
10. Formulation platforms that support lower-dose products with predictable bleeding profiles.

A supplier’s best route is to sell a platform across multiple products rather than depend on Mirena alone. The same technical capabilities can support other implantable delivery systems, vaginal rings, depot products, and long-acting contraceptive devices.

Key Takeaways

• Mirena is a levonorgestrel-silicone reservoir mounted on a polyethylene, barium sulfate-containing intrauterine frame.
• Its relevant “excipient” strategy is a combination-product materials strategy.
• Silicone elastomers and rate-controlling membranes are the most important formulation components.
• Material substitution must preserve release kinetics, biocompatibility, sterility, mechanical performance, and shelf life.
• Mirena’s initial FDA exclusivity has expired; current barriers include patents, device equivalence, manufacturing validation, trademarks, and clinical differentiation.
• Liletta is the closest U.S. commercial comparator; Kyleena and Skyla compete through lower-dose and smaller-system positioning.
• The main opportunities are specialized materials, automated manufacturing, insertion systems, and follow-on long-acting delivery platforms.
• Mirena-specific revenue is not separately disclosed by Bayer, limiting direct product-level revenue analysis.
• Biosimilar risk does not apply because Mirena is not a biologic.
• Generic and Paragraph IV risks remain relevant but are more complex than for conventional oral levonorgestrel products.

FAQs

Can a new silicone excipient replace Mirena’s current silicone elastomer?

Yes, but the replacement would require comparability evidence covering drug release, impurities, extractables, biocompatibility, sterilization, mechanical performance, and stability. A new silicone grade could trigger regulatory changes even if the finished device appears physically similar.

Is barium sulfate in Mirena a pharmaceutical excipient or a device material?

It is primarily a device material used to make the polyethylene frame radiopaque. Its commercial control is linked to dispersion, mechanical properties, imaging visibility, and biocompatibility.

Can a company launch a levonorgestrel IUS without infringing Mirena patents?

Potentially, if it avoids valid enforceable claims through differences in reservoir design, membrane structure, frame geometry, manufacturing, dosage, or use. Patent clearance must be combined with regulatory and clinical feasibility.

Which component has the highest switching cost in Mirena manufacturing?

The silicone drug reservoir and rate-controlling membrane generally have the highest switching cost because they directly determine release kinetics and require extensive process validation.

Are there commercial opportunities for Mirena-type delivery technology outside contraception?

Yes. The platform may support long-acting intrauterine delivery of other hormones or locally acting agents. Commercial feasibility would depend on drug stability, target exposure, duration, device size, clinical benefit, and regulatory classification.

References

1. Bayer AG. (2024). Annual report 2023. https://www.bayer.com/en/investors/annual-reports

2. U.S. Food and Drug Administration. (2022). Mirena prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021225s043lbl.pdf

3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2024b). Combination products. https://www.fda.gov/combination-products

5. U.S. Food and Drug Administration. (2024c). Intrauterine devices. https://www.fda.gov/medical-devices/contraceptive-devices/intrauterine-devices-iuds